Table 1.
The clinicopathological characteristics of the TCGA included patients
| Characteristic | Cluster 1 | Cluster 2 | P |
|---|---|---|---|
| n | 187 | 211 | |
| Age, mean ± SD | 67.46 ± 11.29 | 68.11 ± 9.79 | 0.536 |
| BMI, mean ± SD | 27.1 ± 5.78 | 26.84 ± 5.57 | 0.670 |
| Sex, n (%) | 0.271 | ||
| Female | 44 (11.1%) | 61 (15.3%) | |
| Male | 143 (35.9%) | 150 (37.7%) | |
| Smoking history, n (%) | 0.071 | ||
| No | 124 (32.2%) | 156 (40.5%) | |
| Yes | 58 (15.1%) | 47 (12.2%) | |
| Lymphatic vessel invasion, n (%) | 0.913 | ||
| Yes | 56 (20.7%) | 67 (24.8%) | |
| No | 69 (25.6%) | 78 (28.9%) | |
| WHO grade, n (%) | < 0.001 | ||
| High | 170 (43%) | 207 (52.4%) | |
| Low | 16 (4.1%) | 2 (0.5%) | |
| AJCC stage, n (%) | 0.114 | ||
| AJCC stage III–IV | 67 (16.9%) | 59 (14.9%) | |
| AJCC stage I–II | 119 (30.1%) | 151 (38.1%) | |
| Distant metastasis, n (%) | 0.528 | ||
| M0 | 92 (45.5%) | 100 (49.5%) | |
| M1 | 6 (3%) | 4 (2%) | |
| Lymph node metastasis, n (%) | 0.902 | ||
| N+ | 58 (16.2%) | 69 (19.3%) | |
| N0 | 108 (30.3%) | 122 (34.2%) | |
| T stage, n (%) | 0.347 | ||
| T2_4 | 112 (30.5%) | 137 (37.3%) | |
| Ta_1 | 60 (16.3%) | 58 (15.8%) | |
| Overall survival, n (%) | 0.005 | ||
| Alive | 119 (29.9%) | 104 (26.1%) | |
| Dead | 68 (17.1%) | 107 (26.9%) | |
| Cancer-specific survival, n (%) | 0.003 | ||
| Alive | 139 (36.2%) | 125 (32.6%) | |
| Dead | 43 (11.2%) | 77 (20.1%) | |
| Progression-free survival, n (%) | 0.005 | ||
| No | 120 (30.2%) | 105 (26.4%) | |
| Yes | 67 (16.8%) | 106 (26.6%) |
AJCC, American Joint Committee on cancer; BMI, body mass index; SD, Standard deviation; WHO, World Health Organization; n, Number